Icosapent ethyl (IPE) could be considered in one in four patients following acute coronary syndrome (ACS), according to data from the CALLINICUS-Hellas Registry, an ongoing prospective multicentre observational study evaluating adherence to lipid-lowering therapy among patients with ACS in Greece.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
